Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

A.A. Loosdrecht*, W. Kern, A. Porwit, P. Valent, S. Kordasti, E. Cremers, C. Alhan, C. Duetz, A. Dunlop, W. Hobo, F. Preijers, O. Wagner-Ballon, N. Chapuis, M. Fontenay, P. Bettelheim, L. Eidenschink-Brodersen, P. Font, U. Johansson, M.R. Loken, J.G. MarveldeS. Matarraz, K. Ogata, U. Oelschlaegel, A. Orfao, K. Psarra, D. Subira, D.A. Wells, M.C. Bene, M.G. Della Porta, K. Burbury, F. Bellos, V.H.J. van der Velden, T.M. Westers, L. Saft, R. Ireland

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.
Original languageEnglish
Pages (from-to)77-86
Number of pages10
JournalCytometry Part B-clinical Cytometry
Volume104
Issue number1
Early online date13 Dec 2021
DOIs
Publication statusPublished - Jan 2023

Keywords

  • consensus
  • ELN
  • flow cytometry
  • myelodysplastic syndromes
  • standardization
  • PROGNOSTIC SCORING SYSTEM
  • CLASSIFICATION
  • DIAGNOSIS
  • CYTOGENETICS
  • CELLS
  • STANDARDIZATION
  • CYTOMORPHOLOGY
  • VALIDATION
  • CONSORTIUM
  • SUBGROUPS

Fingerprint

Dive into the research topics of 'Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group'. Together they form a unique fingerprint.

Cite this